Poly Medicure Q2 Results: Domestic revenue jumps 17%, profit up 5% YoY

Poly Medicure Ltd reported earnings for the September quarter of FY26 on Saturday, November 08, with net profit rising 5% year-on-year to ₹91.83 crore compared with ₹87.45 crore in the same period last

year.

Revenue from operations grew 5.7% to ₹443.9 crore from ₹420 crore a year ago, supported by healthy domestic growth of 16.9%.

Earnings before interest, tax, depreciation, and amortisation (EBITDA) stood at ₹114.68 crore, broadly flat from ₹115.22 crore a year earlier. Operating margins were slightly lower at 25.84%, compared with 27.43% in the corresponding quarter of the previous year.

During the quarter, the company launched eight new products and continued expanding its innovation pipeline, supported by an R&D team of over 80 professionals. The company also maintained healthy liquidity, with cash reserves of ₹1,109.1 crore as of September 30, 2025.

Poly Medicure completed the acquisitions of the PendraCare Group in the Netherlands (cardiology) and Citieffe Group in Italy (orthopaedics), marking a strategic expansion into high-growth segments. So far this year, over 4,300 stents have been implanted under the company’s portfolio, with positive clinical feedback.

The company also received an allotment letter from YEIDA for a 7.16-acre plot at the Medical Devices Park and launched the “Polymed Academy of Clinical Excellence” (PACE) to strengthen clinician engagement through advanced training programmes.

For the first half of FY26, consolidated operating EBITDA and PAT grew 2.6% and 14.5%, respectively, with EBITDA margins tracking close to the higher end of its 25–27% guidance range.

Shares of Poly Medicure Ltd closed marginally higher at ₹1,898 on the NSE on Friday.